1-cyclopentyl-3-methyl-1-oxo-2-pentanaminium chloride | 524950-19-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-cyclopentyl-3-methyl-1-oxo-2-pentanaminium chloride
• 英文别名: (1-cyclopentyl-3-methyl-1-oxopentan-2-yl)azanium;chloride
• CAS: 524950-19-4
• 化学式: C₁₁H₂₁NO*ClH
• 分子量: 219.755
• InChiKey: QOMLWUOJCBLHPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.54
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  43.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-cyclopentyl-3-methyl-1-oxo-2-pentanaminium chloride 、 重氮甲烷 、 氢溴酸 、 乙醚 反应 3.5h， 生成 2-溴-1-环己基乙酮
  参考文献：
  名称：

  Substituted amino ketone compounds

  摘要：

  本发明涉及通式IB—(CH—R1)n—C(═X2)—D  (I)及其药学上可接受的盐，包括立体异构体，用于治疗哺乳动物中的糖耐量受损、糖尿病、高脂血症、代谢性酸中毒、糖尿病神经病和肾病以及由糖尿病引起的后遗症。

  公开号：

  US20030125304A1
• 作为产物：
  描述：

  tert-butyl N-[1-(cyclopentylcarbonyl)-2-methyl butyl]carbamate 以 1,4-二氧六环 、 盐酸 、 甲醇 、 氯仿 、 水 为溶剂， 生成 1-cyclopentyl-3-methyl-1-oxo-2-pentanaminium chloride
  参考文献：
  名称：

  Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels

  摘要：

  本发明提供了本发明的DPIV抑制剂的新用途，以及其相应的药用可接受的酸盐形式，用于降低血压水平。

  公开号：

  US20030176357A1

文献信息

• Indazole derivatives as inhibitors of hormone sensitive lipase
  申请人：Zoller Gerhard

  公开号：US20050197348A1

  公开（公告）日：2005-09-08

  The present invention relates to indazole derivatives of the general formulae I or II having the meanings indicated in the description, to the pharmaceutically useful salts thereof and the use thereof as drugs.

  本发明涉及具有描述中所示含义的一般式I或II的吲唑衍生物，其药用盐以及作为药物的用途。
• [EN] PPAR AGONISTS<br/>[FR] ANTAGONISTES DE PPAR
  申请人：SALK INST FOR BIOLOGICAL STUDI

  公开号：WO2014165827A1

  公开（公告）日：2014-10-09

  Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

  本文提供的化合物和组合物可用于增加PPARδ活性。本文提供的化合物和组合物可用于治疗与PPARδ相关的疾病（例如肌肉疾病、血管疾病、脱髓鞘疾病和代谢性疾病）。
• [EN] PPAR AGONISTS AND METHODS OF USE THEREOF<br/>[FR] AGONISTES DE PPAR ET LEURS MÉTHODES D'UTILISATION
  申请人：SALK INST FOR BIOLOGICAL STUDI

  公开号：WO2016057322A1

  公开（公告）日：2016-04-14

  Provided herein are deuterated compounds and compositions useful in increasing PPAR5 activity. The compounds and compositions provided herein are useful for the treatment of PPAR5 related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

  本文提供了用于增强PPAR5活性的氘化合物和组合物。本文提供的化合物和组合物可用于治疗与PPAR5相关的疾病（例如肌肉疾病、血管疾病、脱髓鞘疾病和代谢性疾病）。
• Arylcycloalkyl derivatives having branched side chains, processes for their preparation and their use as pharmaceuticals
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040209873A1

  公开（公告）日：2004-10-21

  Arylcycloalkyl derivatives having branched side chains, processes for their preparation and their use as pharmaceuticals The invention relates to arylcycloalkyl derivatives having branched side chains and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistence is involved.

  含有分支侧链的芳基环烷衍生物、其制备方法以及作为药物的用途。该发明涉及具有分支侧链的芳基环烷衍生物及其生理上可接受的盐和生理功能衍生物。描述的是符合以下公式I的化合物，其中基团如定义所示，以及它们的生理上可接受的盐和制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢紊乱、葡萄糖利用紊乱以及胰岛素抵抗相关疾病。
• Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040204462A1

  公开（公告）日：2004-10-14

  Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals The invention relates to diarylcycloalkyl derivatives and to their physiologically acceptable salts, racemates and physiologically functional derivatives. What is described are compounds of the formula I, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistence is involved.

  日记环烷基衍生物，其制备方法及其作为药物的用途。该发明涉及日记环烷基衍生物及其生理上可接受的盐、消旋体和生理功能衍生物。所描述的化合物为式I的化合物，其中基团如所定义，以及它们的生理上可接受的盐和制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢紊乱和葡萄糖利用紊乱以及胰岛素抵抗相关的疾病。